Specifically, every Swiss-Prot sequence containing one or more annotated residues and a link to a PDB structure was aligned to the corresponding sequence of the PDB structure. Standard annotations of Swiss-Prot used include post-translational modifications (MOD_RES), covalent binding of a lipid moiety (LIPID), glycosylation sites (CARBOHYD), post-translational formed amino acid bonds (CROSSLNK), metal binding sites (METAL), chemical group binding sites (BINDING), calcium binding regions (CA_BIND), DNA binding regions (DNA_BIND), nucleotide phosphate binding regions (NP_BIND), zinc finger regions (ZN_FING), enzyme activity amino acids (ACT_SITE) and any interesting single amino acid site (SITE). To ensure that the mapping is accurate, only alignments of two sequences with a sequence identity greater than ninety five percent were used. The annotated positions from Swiss-Prot are then transferred onto the PDB sequence, as long as the position is not aligned to a gap.
Calcium
It is a key component of bones and teeth, contributing to their strength and density.
Calcium also facilitates muscle contraction, nerve transmission, and blood clotting.
It is involved in regulating cellular processes, including hormone secretion and enzyme activation.
Adequate calcium intake is vital for maintaining overall health, particularly during periods of growth and development.
Deficiencies in calcium can lead to conditions such as osteoporosis, rickets, and hypertension.
Researchers utilize various methods to study the impact of calcium on the body, including in-vitro experiments, animal studies, and clinical trials.
PubCompare.ai's AI-driven platform can enhance the reproducibility and accuaracy of calcium research by helping researchers identify the most effective protocols from literature, preprints, and patents, streamlining the research process.
Most cited protocols related to «Calcium»
Specifically, every Swiss-Prot sequence containing one or more annotated residues and a link to a PDB structure was aligned to the corresponding sequence of the PDB structure. Standard annotations of Swiss-Prot used include post-translational modifications (MOD_RES), covalent binding of a lipid moiety (LIPID), glycosylation sites (CARBOHYD), post-translational formed amino acid bonds (CROSSLNK), metal binding sites (METAL), chemical group binding sites (BINDING), calcium binding regions (CA_BIND), DNA binding regions (DNA_BIND), nucleotide phosphate binding regions (NP_BIND), zinc finger regions (ZN_FING), enzyme activity amino acids (ACT_SITE) and any interesting single amino acid site (SITE). To ensure that the mapping is accurate, only alignments of two sequences with a sequence identity greater than ninety five percent were used. The annotated positions from Swiss-Prot are then transferred onto the PDB sequence, as long as the position is not aligned to a gap.
The observed fluorescence is related to the calcium concentration as [5 (link)–7 ]:
where a is a non-negative scalar, b is a scalar offset parameter, and the noise is assumed to be i.i.d. zero mean Gaussian with variance σ2. For the remainder we assume units such that a = 1 without loss of generality. We begin by assuming b = 0 for simplicity, but we will relax this assumption later. (We also assume throughout that all parameters in sight are fixed; in case of e.g. drifting baselines b we could generalize the algorithms discussed here to operate over shorter temporal windows, but we do not pursue this here.) The parameters γi and σ can be estimated from the autocovariance function and the power spectral density (PSD) of
The goal of calcium deconvolution is to extract an estimate of the neural activity
where the ℓ1 penalty on enforces sparsity of the neural activity and the lower triangular matrix G is defined as:
The deconvolution matrix G is banded with bandwidth p for an AR(p) process. Equivalently,
Most recents protocols related to «Calcium»
Example 5
As described above, vidofludimus, in both its free acid form and its calcium salt formulation (vidofludimus calcium), has undergone clinical trials for a variety of immune-related indications. Both formulations depend on the same active substance (vidofludimus) in vivo, and thus the two formulations share the same mechanism of action, pharmacology and toxicology. IMU-838 is the “Polymorph A” of the dihydrate of 1-cyclopentene-1-carboxylic acid, 2-(((3-fluoro-3′-methoxy(1,1′-biphenyl)-4-yl)amino)carbonyl)-, calcium salt (2:1), characterized by an X-ray powder diffraction pattern having characteristic peaks at 2 theta)(±0.2° of 5.91°, 9.64°, 16.78°, 17.81°, 19.81° and 25.41°. The preparation of this “Polymorph A” is described in WO 2019/175396, which is incorporated herein by this reference.
In the following Table 4 the amount (in mg) of active moiety of the compound is converted into μmol.
Example 3
Dissolution of calcium compounds in plaque fluid was simulated using multicomponent thermodynamic speciation modelling, implemented using the software Geochemist's Workbench. The initial plaque fluid composition was modeled after starved plaque fluid from caries-free individuals. To simulate the low pH conditions following eating the initial pH was set to pH 5. Precipitation was suppressed for all minerals except for the mineral being modeled.